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1238Background: Transplant of skeletal myoblasts is an attractive alternative to repair irreversibly damaged myo-
cardium in ischemic heart failure. We investigated whether transplant of myoblasts overexpressing placental
growth factor would stimulate angiogenesis and enhance myoblast survival in a rat heart failure model.
Methods: Three weeks after myocardial infarction, Sprague–Dawley rats in heart failure received intramyocar-
dial injections of Ringer solution (control) or autologous myoblasts, unmodified or transfected with placental
growth factor expression plasmid. Sham-operated animals served as noninfarct controls. Cardiac function
was assessed by echocardiography to 86 days after engraftment. Immunocytochemistry and fluorescence imag-
ing were used to investigate vessel formation, grafted myoblast survival, infarct wall thickness, and infarct size.
Quantitative real-time reverse transcriptase polymerase chain reaction and Western blotting measured tissue
messenger RNA and protein expressions.
Results: Left ventricular function significantly improved with time, and fractional shortening on day 86 was
significantly enhanced in transfected myoblast group relative to control (P< .01) and unmodified myoblast
(P< .05) groups. Vascular density (P< .01) and myoblast survival (P< .05) were enhanced in rats treated
with transfected myoblasts relative to other groups (P<.05). Mean fraction of fibrotic scar tissue was decreased
in unmodified and transfected myoblast groups relative to controls on day 86 (P<.05), and left ventricular wall
thickness was significantly increased in transfected myoblast group relative to other groups (P<.05).
Conclusions: Intramyocardial injections of autologous myoblasts overexpressing placental growth factor im-
proved cardiac function, attenuated adverse cardiac remodeling, induced angiogenesis, and probably enhanced
survival of grafted myoblasts. (J Thorac Cardiovasc Surg 2011;141:1238-45)Heart failure resulting from myocardial infarction is grow-
ing in incidence, and heart transplant is the only accepted
treatment for end-stage patients. Because of organ shortage,
however, such alternative approaches as transplant of autol-
ogous skeletal myoblasts have received tremendous interest
in experimental and human studies.1-4 However, the
MAGIC (Myoblast Autologous Grafting in Ischemic
Cardiomyopathy) trial5 failed to improve cardiac function
in patients although remodeling of the myocardium was
ameliorated. Earlier reports have indicated that the outcome
of myoblast transplant is dependent on the number of
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The Journal of Thoracic and Cardiovascular Surmight be beneficial. Accordingly, experimental studies
have attempted to improve myoblast graft survival by using
colony-stimulating factor 1, hypoxia inducible factor, and
vascular endothelial growth factor (VEGF).6-8
Placental growth factor (PlGF) is a VEGF homolog that
is predominantly expressed in the placenta, heart, and
lung.9 Although VEGF and PlGF have synergistic effects,10
PlGF binds exclusively to the fms-like tyrosine kinase
(FLT1) receptor and the neuropilin 1 coreceptor.9 PlGF is
proangiogenic and induces chemotactic, proliferative, and
survival signals for cells reportedly involved in arteriogen-
esis, such as endothelial cells, smooth muscle cells, and
monocytes.11,12 Whether myoblasts engineered to
overexpress PlGF could improve cardiac function is
unknown, so we addressed this issue.MATERIALS AND METHODS
Experimental Design and Animals
All experiments were approved by the ethics committee of the Medical
University of Vienna, and the investigation conformed to the Guide for the
Care and Use of Laboratory Animals published by the US National Insti-
tute of Health (NIH Publication No. 85–23, revised 1996; www.nap.edu/
catalog/5140.html). A total of 95 Sprague–Dawley rats (240–280 g, 8–10
weeks old) were used (Harlan Laboratories, Inc, Boxmeer, The Nether-
lands). Myocardial infarction was induced in 75 anesthetized animals,6gery c May 2011
FIGURE 1. Left ventricular function. Only group treated with myoblasts
transfected with placental growth factor (MB-PlGF) showed improved
fractional shortening (FS) significantly with time, whereas in group treated
with unmodified myoblasts (MB) and control group, fractional shortening
values on days 52 and 86 were not significantly different from values on
day 21. In all infarct groups, fractional shortening was lower than in
sham groups. Fractional shortening on day 86 in group with transfected
myoblasts was higher than fractional shortening on day 86 in group with
unmodified myoblasts (P<.05) and control group (P<.01). Asterisk indi-
cates significant difference from sham group (P<.05). Dagger indicates
significant differences on days 21 and 52 versus day 86 (P<.05).
Abbreviations and Acronyms
a-SMA ¼ a-smooth muscle actin
DiIC18 ¼ 1,10-dioctadecyl-3,3,30,30-
tetramethylindocarbocyanine
perchlorate
EF ¼ ejection fraction
FLT1 ¼ fms-like tyrosine kinase
FS ¼ fractional shortening
KDR ¼ kinase insert domain receptor
LV ¼ left ventricular
LVEDD ¼ left ventricular end-diastolic
diameter
LVESD ¼ left ventricular end-systolic diameter
MB ¼ unmodified myoblast transplant
[group]
MB-PlGF ¼ myoblast overexpressing placental
growth factor transplant [group]
MMP ¼ matrix metalloproteinase
PlGF ¼ placental growth factor
TIMP ¼ tissue inhibitor of matrix
metalloproteinase
VEGF ¼ vascular endothelial growth factor
vWF ¼ von Willebrand factor
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Sand cardiac function was assessed in surviving animals (n¼ 45) by echocar-
diography on day 21. The rats with comparable fractional shortening (FS)
were divided into 3 groups of 15; they then underwent rethoracotomy,
and 150 mL Dulbecco modified Eagle medium containing 5 3 106 myo-
blasts labeled with 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine
perchlorate (DiIC18) or 150 mL Ringer solution were injected into the
infarcted myocardium with a 30-gauge needle.6 The volume delivered
was evenly divided between the central (2 injections) and bordering (5 in-
jections) areas of the infarcted myocardium. Animals were treated by intra-
myocardial injection of 5 3 106 autologous myoblasts overexpressing rat
PlGF (MB-PlGF group), unmodified myoblasts (MB group) or Ringer solu-
tion (control group). Sham-operated rats (n ¼ 20) served as additional non-
infarct controls (sham group). On days 52 and 86, cardiac function was
reassessed.
Plasmid Construction, Myoblast Culture, and
Transfection
The 477–base pair rat PlGF open reading frame13 was amplified by
polymerase chain reaction from an Image clone (7193034; ATTC
10467199, Genbank BC087006, CK603317) with 50-AAGATGCTGGC
CATGAAGCT-30 forward and 50-TCACAGGTGGGGTTCCTCAG-30 re-
verse primers with high-fidelity platinum Taq polymerase (Invitrogen
GmbH, Lofer, Austria). The polymerase chain reaction product was sepa-
rated on 1% agarose gels by electrophoresis, purified with Qiaex II (QIA-
GEN GmbH, Hilden, Germany), and topoisomerase I–mediated TA
cloning cloned under control of the cytomegalovirus immediate early pro-
moter into pcDNA2.1/V5-His-TOPO (Invitrogen) as p(r)PlGF. The reverse
primer design maintained the natural PlGF stop codon to prevent transla-
tion of the V5 epitope in the expression construct. Plasmids were prepared
with Genelute (Sigma, St Louis, Mo) maxipreps, and the inserts were con-
firmed by sequencing with a T7 primer on an ABI 3100 genetic analyzer
(Life Technologies Corporation, Carlsbad, Calif).The Journal of Thoracic and CarBefore myocardial infarction was induced, the right anterior tibial mus-
cle was isolated, minced in phosphate-buffered saline solution, and passed
through a 100-mm sieve (BD, Franklin Lakes, NJ). Cells were cultured in
Dulbecco modified Eagle medium supplemented with 10% fetal calf
serum,6 screened with myocyte-specific antidesmin (Lab Vision/
NeoMarkers, Fremont, Calif) and fibroblast-specific antibody (Harlan
Sera-Lab Ltd, Loughborough, UK), and transfected with the p(r)PlGF or
empty vector with Effecten transfection reagent (QIAGEN). Transfection
efficiency was determined6 and was approximately 70%.
Echocardiography and Electrocardiography
Rats were anesthetized with isoflurane, and the maximal left ventricular
(LV) long-axis length and endocardial area tracing were measured with
a 15-MHz linear array scan head to calculate LV end-diastolic diameter
(LVEDD), LV end-systolic diameter (LVESD), end-diastolic volume
(LVEDV), and end-systolic volume (LVESV).6 LV FS and ejection fraction
(EF)were calculated according to the following formulas: FS¼ [(LVEDD
LVESD)/LVEDD] 3 100% and EF ¼ [(LVEDV  LVESV)/
LVEDV]3 100%. Measurements used 3 consecutive cardiac cycles. A te-
lemetry device (Data Sciences International, Minneapolis, Minn) recorded
electrocardiographic signals continuously6 (http://cardiovascres.oxford
journals.org/content/79/3/395.long).
Histology
Tissue was processed for paraffin and cryosectioning embedding.6 Se-
rial sections were stained with hematoxylin–eosin and Goldner trichrome
for evaluation of myocardial scar fibrosis and LV infarct wall thickness.
For histologic quantification of DiIC18-labeled myoblasts, serial heart sec-
tions were counterstained with 4,6-diamidino-2-phenylindole (Molecular
Probes, Inc, Eugene, Ore) and embedded in AF1 antifading agent (Citifluordiovascular Surgery c Volume 141, Number 5 1239
TABLE 1. Echocardiographic data on day 86
Parameter Control MB MB-PlGF
LVEDD (cm) 0.8  0.13 0.68  0.08 0.65  0.15*
LVESD (cm) 0.61  0.14 0.5  0.09 0.4  0.1yz
LVEDV (mL) 1.7  0.2 1.6  0.1 1.4  0.2*
LVESV (mL) 1.4  0.3 1.2  0.2 1  0.1yz
Ejection fraction (%) 22  7 24  8 34  6x
MB, Unmodified myoblast group;MB-PlGF, myoblast group overexpressing placen-
tal growth factor; LVEDD, left ventricular end-diastolic diameter; LVESD, left ven-
tricular end-systolic diameter; LVEDV, left ventricular end-diastolic volume;
LVESV, left ventricular end-systolic volume. *P < .05 versus control group.
yP < .01 versus control group. zP < .05 versus unmodified myoblast group.
xP<.01 versus control and unmodified myoblast groups.
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SLtd, Leicester, UK). For immunohistochemistry, deparaffinized sections
were incubated with 3% hydrogen peroxide, blocked in 5% horse serum
(Jackson ImmunoResearch Laboratories, Inc, West Grove, Pa) and then in-
cubated with a polyclonal anti–rat von Willebrand factor (vWF; Abcam,
Cambridge, UK) or a monoclonal anti–a-smooth muscle actin (a-SMA;
Sigma) antibody. Primary antibodies were detected with appropriate bioti-
nylated secondary antibodies (Vector Laboratories, Inc, Burlingame, Calif)
and peroxidase-conjugated streptavidin (DakoNorth America, Inc, Carpin-
teria, Calif) developed with 3,30-diaminobenzidine (Vector Laboratories),
and counterstained with hematoxylin. For quantitative histologic analysis,
digitized images were made at 403magnification. Quantification was per-
formed with Lucia G image analysis software (Lucia G; OPTOTEAM
Pr€azisionsinstrumente, Vienna, Austria). Three randomly chosen fields of
the myocardial wall in the region of the anterior branch of the left coronary
artery were evaluated in each heart. Vascular density, vWF-positive cells,
and a-SMA positive cells were all evaluated.
Fluorescence Optical Imaging
In experiments with DiIC18-labeled myoblasts, 3-dimensional cellular
integration was assessed on an imaging station for all animals (KodakFIGURE 2. Cardiac remodeling in infarcted hearts. Representative histologic i
portion of fibrotic tissue to normal left ventricular (LV) myocardium is decrease
fected myoblast group (MB-PlGF) relative to control group. Asterisk indicates si
wall thickness is increased in transfected myoblast group relative to unmodified
sham group. Dagger indicates significant differences from unmodified myobla
1240 The Journal of Thoracic and Cardiovascular SurIS2000MM; Eastman Kodak Company, New Haven, Conn). Ventricles
were then dissected in 5 animals per group and mechanically dissociated
in collagenase, and the percentage of grafted DiIC18-labeled myoblasts
was detected with an inverted fluorescent microscope.
Real-Time Reverse Transcriptase Polymerase Chain
Reaction Analysis
Real-time reverse transcriptase polymerase chain reaction analysis was
performed as described.6 The primer sequences (sense/antisense)were as fol-
lows: PlGF, 50-ACTGTGTGGCGCTAAAGACA-30/50-TTCCTCAGTCTG
TGGGGTTT-30; VEGF-A, 50-TCCTGCAGCATAGCAGATGT-30/50-GCG
AGTCTGTGTTTTTGCAG-30; kinase insert domain receptor (KDR), 50-
GGAGATTGAAAGAAGGAAC-30/50- ACTTCCTCTTCCTCCATAC-30;
FLT1, 50-GGAGGCGAGGATTACAGTGA-30/50-GGAGGCGAGGATTA
CAGTGA-30; b2-microglobulin (as a housekeeping gene), 50-ACTGCT
ACGTGTCTCAGTTC-30/50-CAAGCATATACATCGGTCTC-30.
Western Blotting
Western blots were probed with polyclonal antibodies against PlGF
(Santa Cruz Biotechnology, Inc, Santa Cruz, Calif), VEGF-A (Thermo
Fisher Scientific, Waltham, Mass), matrix metalloproteinases (MMPs) 2,
and 9, tissue inhibitors of MMP (TIMPs) 1, 2, 3, and 4 (Millipore Corpo-
ration, Billerica, Mass).6
Statistical Analysis
Data were compared between the groups with the Wilcoxon rank test
and analysis of variance with the Bonferroni t test after testing for normal-
ity of distribution by Kolmogorov–Smirnov test. The echocardiographic
data were subjected to repeated-measures analysis of variance by using
the repeated statement in the mixed procedure. Post hoc comparisons
were performed with the Tukey–Kramer method of adjustment for multiple
comparisons. Statistical analyses were performed with the SAS software
system for Windows version 9.1.3 and Enterprise Guide version 4.1
(SAS Institute, Inc, Cary, NC). Data are expressed as mean  SD.mages (A) and quantitative morphometric analysis (B and C). B, Mean pro-
d in unmodified myoblast group (MB) and in placental growth factor–trans-
gnificant difference from control group (P<.05). C, Left ventricular infarct
myoblast and control groups. Asterisk indicates significant difference from
st and control groups (P<.05).
gery c May 2011
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Transplant of Myoblasts Overexpressing PlGF
Improves LV Function
Three weeks after myocardial infarction, FS was compa-
rable among all treatment groups and significantly de-
creased relative to the sham group. FS was significantly
improved on days 52 (P< .05) and 86 (P< .05) relative
to day 21 in the MB–PlGF group but was not statistically
different within the MB and control groups (Figure 1). In
all experimental groups, the FS was significantly lower
than in sham-operated animals on day 86. On day 86, FS
in the MB-PlGF group was significantly higher than FS
values on day 86 in the MB (P < .05) and control
(P<.01) groups.
On day 86, LVEDVand LVEDDwere reduced in theMB-
PlGF group relative to the control group (P<.05); so were
LVESV and LVESD relative to both the control group
(P<.01) and the MB group (P<.05). Consequently, EF
was higher in the MB-PlGF group than in both the MB
and control groups (P<.01; Table 1). Electrocardiographic
recordings revealed ventricular arrhythmias in both the MB
and MB-PlGF groups after myoblast engraftment, but these
were self-limiting and hemodynamically well tolerated.
These results clearly demonstrate that the transplant of
myoblasts engineered to overexpress PlGF improves long-
term cardiac function.FIGURE 3. Fluorescent autologous myoblasts. A, Localization of myo-
blasts labeled with 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine
perchlorate, both unmodified (MB) and overexpressing placental growth
factor (MB-PlGF) 86 days after myocardial infarction. B, Representative
white-light images (left), fluorescent 1,10-dioctadecyl-3,3,30,30-tetramethy-
lindocarbocyanine perchlorate (DiIC18) signals (center), and merged im-
ages (right) showing cellular localization (red) in infarcted area of heart
(asterisk). LV,Left ventricle; RV, right ventricle. Atria are removed. B, Rep-
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Attenuates Cardiac Remodeling
Morphometric analysis revealed that the mean fraction of
fibrotic scar tissue to normal LV myocardium was de-
creased in the MB and MB-PlGF groups relative to the con-
trol group when killed on day 86 (P<.05; Figure 2, A and
B). The LV wall thickness, however, was significantly in-
creased in the MB-PlGF group relative to both the MB
and control groups (P<.05; Figure 2, C). All experimental
groups had a significantly reduced wall thickness relative to
the sham group. These results further indicate that PlGF
ameliorates cardiac remodeling associated with ischemia-
induced heart failure.resentative red-channel fluorescence images of 1,10-dioctadecyl-3,3,30,30-
tetramethylindocarbocyanine perchlorate signal merged with correspond-
ing section counterstained with 4,6-diamidino-2-phenylindole in border
zone of unmodified (MB) and transfected (MB-PlGF) myoblast groups.
Bar represents 50 mm. HE, Hematoxylin–eosin. C, Analyses revealed sig-
nificantly more grafted fluorescent myoblasts labeled with 1,10-diocta-
decyl-3,3,30,30-tetramethylindocarbocyanine perchlorate (DiI) in
transfected myoblast group (MB-PlGF) relative to unmodified myoblast
(MB) group in tissue lysates. Asterisk indicates significant difference
from unmodified myoblast group (P<.05).Fluorescent Myoblast Survival
Shown representatively in Figure 3, A, fluorescent
myoblasts in the anterior LV wall were seen in the MB-
PlGF andMB groups. Analysis of serial sections by fluores-
cence microscopy confirmed these data and revealed that
fluorescent myoblasts were visible within the myocardial
tissue in both groups (Figure 3, B). Ventricles were mechan-
ically dissociated in collagenase, and the percentage of
grafted DiIC18-labeled myoblasts was determined with an
inverted fluorescent microscope. More grafted, fluorescent,
DiIC18-labelled myoblasts were seen in theMB-PlGF group
than in the MB group (P<0.05; Figure 3, C).The Journal of Thoracic and CarPlGF Enhances Angiogenesis
Histologic analysis in the border zone of the infarct area
revealed a significantly increased number of vWF-positivediovascular Surgery c Volume 141, Number 5 1241
FIGURE 4. Analysis of angiogenesis. Representative sections stained for vonWillebrand factor (vWF) in (A) unmodified myoblasts (MB) and (B) placen-
tal growth factor–transfected myoblasts (MB-PlGF).Representative sections stained for a-smooth muscle actin (a SMA) in unmodified myoblast (C, E) and
transfected myoblast (D, F) groups. Quantification of vonWillebrand factor–positive (vWFþ, G) or a-smooth muscle actin–positive (a SMAþ, H) vessels 86
days after infarction (count per high-power field, HPF) showing increased vessel density in transfected myoblast group. Asterisk indicates significant
Evolving Technology/Basic Science Gmeiner et al
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Svessels in the MB-PlGF group relative to both the MB and
control groups (P<.01; Figure 4, A, B, and G) 86 days after
myocardial infarction. Furthermore, the number of
a-SMA–positive vessels was increased in the MB-PlGF
group relative to both the MB and control groups
(P<.01; Figure 4, C–F and H). Transfection efficiency in
cultured myoblasts was approximately 70%. PlGF messen-
ger RNAwas overexpressed in vitro on days 2, 7, and 14 rel-
ative to expression in untransfected control myoblasts
(Figure 4, I).
In line with these findings, we observed significant upre-
gulation of VEGF-A, KDR, and FLT1 messenger RNA on
day 86 in the MB-PlGF group (P<.05; Figure 4, J–L) rel-
ative to sham, control, and MB groups. PlGF messenger
RNA expression (Figure 4,M) and VEGF-A protein expres-
sion (Figure 4, N) were the same in all experimental groups.
PlGF protein expression was significantly increased in the
MB and MP-PlGF groups relative to the sham and control
groups (P< .05; Figure 4, O). These results indicate that
PlGF enhances angiogenesis.
PlGFAffects Myocardial MMP and TIMP
Expressions
On day 86 after myocardial infarction, protein expres-
sions of the key angiogenic proteases MMP-2 and
MMP-9 were significantly upregulated in the MB-PlGF
group relative to all other groups (Figure 5, A and B). In ad-
dition, significant increases in TIMP-1 and TIMP -2 expres-
sions were seen in the MB-PlGF group relative to the sham,
control, and MB groups (Figure 5, C and D). Myocardial
TIMP-3 protein expression was significantly increased in
both the MB and MB–PlGF groups relative to the sham
and control groups (Figure 5, E), although TIMP-4 was
downregulated in sham and both myoblast groups relative
to the control group (Figure 5, F). These data indicate that
PlGF overexpression enhances the protein expression of an-
giogenic MMPs and differentially affects the protein ex-
pressions of their tissue inhibitors.
DISCUSSION
In a series of experiments, it has been shown that loss of
PlGF impairs pathologic angiogenesis in the ischemic limb
and heart without affecting physiologic angiogenesis.10
Conversely, PlGF treatment has been shown to stimulate
angiogenesis and collateral growth in the ischemicdifference from control and unmodifiedmyoblast groups (G, H, P<.01). Bar represents 50 mm (A, B, E, F) or 100 mm (C, D). I, Changes in placental growth
factor (PlGF) messenger RNA (mRNA) levels after transfection of myoblasts with placental growth factor plasmids in vitro relative to controls. Asterisk
indicates significant difference from control (P< .001). Quantification of messenger RNA (mRNA) levels of vascular endothelial growth factor A
(VEGF-A, J), placental growth factor (PlGF, K), fms-like tyrosine kinase (Flt-1, L), and kinase insert domain receptor (KDR,M), and protein levels of vas-
cular endothelial growth factor A (VEGF-A, N) and placental growth factor (PlGF, O) 86 days after myocardial infarction. Asterisk indicates significant
difference from sham, control, and unmodifiedmyoblast groups in J (P<.05).Asterisk indicates significant difference from sham group and dagger indicates
significant difference from control and unmodified myoblast groups in L (P<.05). Asterisk indicates significant difference from sham, control, and unmod-
ified myoblast groups in M (P<.05). Asterisk indicates significant difference from sham group in O (P<.05). LC, Loading control; SP, specific protein.
:The Journal of Thoracic and Carmyocardium and limb.15 Recently, it has been shown that
systemic delivery of PlGF, resulting in elevated circulating
levels of PlGF for 4 weeks, can improve cardiac function
and stimulates angiogenesis in the infarct border and vessel
enlargement in the remote myocardium.16 Furthermore, in-
tramyocardial delivery of PlGF after myocardial infarction
enhances angiogenesis in the border zone and attenuates
adverse ventricular remodeling while preserving cardiac
function.17 Myoblast transplant into the ischemic heart
has been shown to exert beneficial effects after experimen-
tal myocardial infarction.1-3 Nonetheless, in the first clinical
study, myoblast transplant into the ischemic heart failed to
improve cardiac function, although distinct antiremodeling
effects were achieved.5 On the other hand, various experi-
mental studies have indicated that the combination of myo-
blasts with growth factors can expand the efficiency of
myoblast transplant.6,7 Our study was therefore designed
to create genetically engineered myoblasts overexpressing
PlGF and to investigate their role in angiogenesis,
myoblast survival, cardiac remodeling, and cardiac
function in an experimental heart failure model. The
beneficial role of PlGF after acute myocardial infarction
is well documented,10,12,15-17 and PlGF has been shown to
exert positive effects on vessel maturation and vessel
durability, influencing endothelial cells, smooth muscle
cells, and macrophages. Smooth muscle cells in particular
are crucial for arteriogenesis, because vessels covered
with smooth muscle cells fail to regress, even when the
angiogenic stimulus fades away.12
We observed significantly more vWF-positive and a-
SMA–positive vessels and upregulated VEGF-A, FLT1,
and KDR gene expressions in the MB-PlGF group.
VEGF-A plays a key role in angiogenesis9 and induces
blood vessel formation after experimental myocardial in-
farction.8 The VEGF receptors FLT1 and KDR are impor-
tant for endothelial cell differentiation, migration,
proliferation, and angiogenesis.9 There were no significant
differences in PlGF messenger RNA expression in myocar-
dial tissue among all experimental groups on day 86. PlGF
protein expression, however, was increased in both the MB
and MB-PlGF groups relative to the sham group. This find-
ing has 2 potential implications. First, acute myocardial
infarction per se could have contributed to PlGF overex-
pression, as previously reported.14 Second, because vascu-
lar density and cardiac function were improved in thediovascular Surgery c Volume 141, Number 5 1243
FIGURE 5. Matrix metalloproteinase (MMP) and tissue inhibitor of ma-
trix metalloproteinase (TIMP) protein expressions in sham, control, un-
modified myoblast (MB), and transfected myoblast groups (MB-PlGF).
Asterisk indicates significant difference from sham group (P<.05 for con-
trol and unmodified myoblast groups, P<.001 for transfected myoblast
group) and dagger indicates significant difference from control and un-
modified myoblast groups (P<.001 for control and P<.05 for unmodified
myoblasts) in A. Asterisk indicates significant difference from sham, con-
trol, and unmodified myoblast groups (P<.0001) in B. Asterisk indicates
significant difference from sham group (P<.01 for control and unmodified
myoblast groups, P<.05 for transfected myoblast group) and dagger indi-
cates significant difference from control and unmodified myoblast groups
(P<.05) in C. Asterisk indicates significant difference from sham group
(P<.01 for control group, P<.001 for unmodified myoblast group, and
P<.05 for transfectedmyoblast group) and dagger indicates significant dif-
ference from control and unmodified myoblast groups (P<.05) in D. As-
terisk indicates significant difference from sham and control groups
(P< .05 for unmodified myoblast group vs sham and control groups,
P<.001 for transfected myoblast group vs sham and control groups) in
E. Asterisk indicates significant difference from control group (P<.001)
in F. LC, Loading control; SP, specific protein.
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SMB-PlGF group but not in the MB group, we assume that
transient PlGF overexpression may provide enormous ben-
efits in the repair of infarcted myocardium as result of the
prolonged production of angiogenic factors by myoblasts
that overexpress PlGF and induce the formation of durable
vessels, as shown by our results. This hypothesis is further
supported by the fact that in our experimental setting myo-
blasts transfected with PlGF overexpressed PlGF in vitro for
at least 14 days. These results are also in line with data
showing that PlGF enhances angiogenesis and arteriogene-
sis within 7 days in ischemic myocardium.12
In addition to angiogenesis, FS was increased relative to
baseline levels on days 52 and 86 in the MB-PlGF group.
Although higher mean values on days 52 and 86 relative
to baseline levels were also found in the MB group, those
results did not reach statistical significance. Moreover, FS
on day 86 in the MB-PlGF group was significantly im-
proved relative to FS on day 86 in both the MB and control
groups. Importantly, on day 86 LV diameters, LV volumes,
and consequently EF were significantly improved in the
MB-PlGF group. These results clearly demonstrate the ben-
eficial effect of MB-PlGF on cardiac function.
We also investigated the influence of MB-PlGF on myo-
blast graft survival. It has been reported previously that the
outcome of myoblast transplant is dependent on the number
of grafted cells,3 and our results are in line with this finding.
Fluorescent imaging revealed significant differences in the
size of the area containing myoblasts between the MB
and MB-PlGF groups. In addition, the number of labeled
cells was significantly increased in the MB-PlGF group.
These results indicate that PlGF exerts beneficial effects
on myoblast survival that positively contribute to angiogen-
esis and cardiac function. In this study, we did not perform
additional staining for surviving myoblasts; however, our
previous work clearly points to a high correlation between
DiIC18 fluorescence and skeletal muscle myosin heavy
chain staining.6
Although we found a significant reduction in LV fibrosis
in both the MB and MB-PlGF groups relative to the control
group, the largest LV infarct wall thickness was seen in the
MB-PlGF group. In this study, unmodified myoblasts re-
duced cardiac fibrosis, but our results also indicate that
these antiremodeling effects of unmodified myoblasts can-
not contribute to the improvement of cardiac function, LV
infarct wall thickness, or enhanced vessel formation.
MMPs and TIMPs are involved in extracellular matrix turn-
over in both physiologic and pathologic situations.18 It has
been reported that MMPs are increased after acute myocar-
dial infarction and that MMP inhibitors beneficially affect
cardiac remodeling and function,18 although another study
indicates that prolonged MMP inhibition does not prevent
LV remodeling and dysfunction but rather impairs postin-
farct angiogenesis,19 associated with higher mortality.20
An excessive fibrosis in the absence of contractility orgery c May 2011
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and decrease cardiac function. On this basis, increased ex-
pression of MMPs and proteolysis of excess collagen may
be a protectivemechanism in chronic myocardial infarction.
Myoblasts in combination with relaxin are reported to upre-
gulate MMP-2, MMP-9, and VEGF expressions, resulting
in enhanced angiogenesis and improved cardiac function.21
In concert with these findings, our treatment protocol
resulted in overexpression of both MMP-2 and MMP-9,
enzymes that reportedly mediate angiogenesis.21-23 The
myocardial MMP profile in the MB-PlGF group therefore
suggests that myoblasts transfected with PlGF positively in-
fluence cardiac tissue remodeling through MMP-2 and
MMP-9 upregulation. This effect may also comediate
PlGF-induced angiogenesis, because that process is depen-
dent on degradation of extracellular matrix components.
Finally, the delivery of the PlGF gene by myoblast trans-
plant resulted in differentially expressed TIMPs. The reason
for this phenomenon is unclear; however, earlier results on
the positive effects of TIMP-3 on cardiac remodeling in
a knockout model24 may point to the contribution of this
enzyme, at least in part, to the observed reverse cardiac
remodeling.
In sum, we have demonstrated that PlGF-transfected
myoblasts induce angiogenesis, enhancemyoblast graft sur-
vival, improve cardiac function, and ameliorate cardiac re-
modeling. This approach may be beneficial in the treatment
of chronic heart failure. As a limitation of this study, how-
ever, we acknowledge that fluorescent imaging of surviving
myoblasts, even though fluorescent cells have been detected
in tissue lysates and quantified, might not be as powerful as
detection of chromosomes by transplanting myoblasts in
sex-mismatched groups. Also, although our findings were
statistically significant, the fact that not all animals were
studied with in vivo imaging and fluorescent microscopy
may have had some effect on the results that was not ac-
counted for in data interpretation.
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